Boston Scientific Corporation Highlights 6 Months Data of MODULAR ATP Study & 5 Years Data of APPRAISE ATP Study at Heart Rhythm 2024
Shots:
- The MODULAR ATP study assessed the safety & efficacy of the mCRM system (EMBLEM S-ICD & EMPOWER Leadless Pacemaker) & EMPOWER LP plus its communication with EMBLEM S-ICD for painless ATP therapy, rate-responsive bradycardia pacing & sudden cardiac death prevention without heart or sternum leads. The FDA’s approval is expected in 2025
- EMPOWER LP implantation leads to 97.5% major complication-free rate; 98.8% communication success rate from EMBLEM S-ICD System to EMPOWER LP; 61.3% ATP success rate & ≤2.0V at 0.4ms pacing capture threshold in 97.4% patients
- The APPRAISE ATP study of ATP as a method of ventricular tachycardia termination in PP patients (n= 2,626) depicted first all-cause shock reduction in 1% of them per yr. with similar shock burden in both arms without requiring ATP therapy in patients across the ATP-plus-shock arm
Ref: Boston Scientific | Image: Boston Scientific
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
